Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Orfoglipron (Foundayo) label shortcomings Just looked into the PI (label) of Foundayo (Orfoglipron) We all knew that the efficacy will not be has high as injecatables or Wegovy Pill and it will most likely be somewhat less tolerable But I am really surprised about some of the other things that are on the label: There is reference to DDI with Simvastatin - this is a big problem for many as so many people on AOM also use Statins. I remember Novo CEO made a reference to this at JPM congress back in January and Dave Ricks said it’s a non-issue , well it happens to be in the label now. There is also a warning for Women who are on birth control pills (contraceptives) as they have to stop 30 days before starting the Orfo medication- this is also a major issue as many patients are women and will not want to chose between their birth control pill and their anti obesity medication. And to top it all off, unusually there is specific issue with Foundayo and hair loss !

Lilly soll den bumms hier einfach übernehmen, dann hätten wir endlich Ruhe

Ist es nicht. Im Bereich der Adipositas Medikamente - und darauf beruhte nun Mal der Hype bei Novo - ist Lily Meilenweit voraus. Die Drecksfirma ist Novo. Alleine schon mit ihrer Informationspolitik den Aktionären gegenüber.

Ich hasse diese Drecks ami Firma. Alles nur Show

Ich hasse diese Drecks ami Firma. Alles nur Show

Lily heute packt heute 45mrd marktkapitalisierung drauf wegen der pille...

hat wohl doch nicht so viel wie 36mg

LLY: "We conducted the Phase 3 program in capsules & conducted a bioequivalence study comparing capsules to tablets. Below is a table that shows the Phase 3 capsule dose and approved equivalent Foundayo tablet. The 17.2mg tablet would deliver the same results as the 36mg capsule"